PROK · Prokidney Corp. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current operating plan, we do not believe our existing cash and cash equivalents and marketable securities as of June 30, 2026, will be sufficient to fund our obligations for the 12 months following the issuance of the unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q on August 10, 2026. Accordingly, substantial doubt exists about our ability to continue as a going concern within one year after the date the unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q are issued.”View the 10-Q filed Aug 10, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $818K | $893K | $76K | $0 | $0 | — | — | |
| $130.92M | $114.12M | $127.67M | $106.71M | $82.07M | $46.26M | $21.04M | |
| $47.12M | $51.78M | $56.08M | $44.82M | $70.94M | $8.86M | $5.98M | |
| — | $0 | $0 | $213K | $215K | $214K | $215M | |
| $6.85M | $6.58M | $5.43M | $3.85M | $3.04M | $1.98M | $964K | |
| $178.03M | $165.9M | $183.75M | $151.52M | $153.01M | $55.11M | $27.02M | |
| -$177.22M | -$165.01M | -$183.68M | -$151.52M | -$153.01M | -$55.11M | -$27.02M | |
| — | -18477.83% | -241678.95% | — | — | — | — | |
| -$170.37M | -$158.43M | -$178.24M | -$147.67M | -$149.97M | -$53.13M | -$26.06M | |
| $19K | $4000 | $9000 | $12K | $215K | $0 | $0 | |
| $2.14M | $3.42M | $7M | $6.02M | $0 | — | — | |
| -$166.78M | -$151.2M | -$163.93M | -$129.45M | -$147.24M | -$55.11M | -$26.98M | |
| -$1.03M | $414K | -$598K | $6M | $896K | $38K | -$232K | |
| -$84.16M | -$68.99M | -$61.19M | -$35.47M | -$148.14M | -$55.15M | -$26.75M | |
| — | -7725.2% | -80507.89% | — | — | — | — | |
| -$84.22M | -$69.06M | -$61.19M | -$35.34M | -$108.03M | -$55.15M | — | |
| USD/shares | — | — | — | — | -$0.23 | — | — |
| USD/shares | — | — | — | — | -$0.23 | — | — |
| shares | — | — | — | — | 61.54M | — | — |
| shares | — | — | — | — | 61.54M | — | — |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2021–FY2025: $9.5M in buybacks.
Debt Profile
Completed filing coverage through Mar 18, 2026Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Finance lease liabilities | 2026-06-30 | USD 67,000 | 10-Q filed 2026-08-10 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
| Operating lease liabilities | 2026-06-30 | USD 3,456,000 | 10-Q filed 2026-08-10 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 325 similar-size Biotechnology companies (of 563 listed).